Patients whose metastatic colorectal cancer is refractory to standard therapies benefit from a new combination agent TAS-102 after it was found to improve the overall survival compared to placebo, a new study presented at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona reveals. "Around 50% of patients with colorectal cancer develop metastases but eventually many of them do not respond to standard therapies," said Takayuki Yoshino of the National ...Sunday 29 June 2014
Survival Chances Improved Through TAS-102 in Metastatic Colorectal Cancer Refractory to Standard Therapies
Patients whose metastatic colorectal cancer is refractory to standard therapies benefit from a new combination agent TAS-102 after it was found to improve the overall survival compared to placebo, a new study presented at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona reveals. "Around 50% of patients with colorectal cancer develop metastases but eventually many of them do not respond to standard therapies," said Takayuki Yoshino of the National ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment